AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05053880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT001
Description: Phase1b - Starting approximately 2 weeks prior to the scheduled surgery, patient will receive an assigned dose of ACT001 by mouth in combination with a single dose of 200 mg pembrolizumab via an intravenous (IV-through a tube in vain) infusion in the clinic. Then patient will self administer ACT001 capsules twice daily by mouth, at the dose to which patient is assigned, until the evening prior to scheduled surgery. Patient will then undergo surgery to remove all or part of tumor. This a standard 3+3 dose escalation.
Study NCT05053880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT001 + Pembrolizumab
Description: Phase 2a - Starting approximately 2 weeks prior to the scheduled surgery, patient will receive a single dose of 200 mg pembrolizumab via an intravenous (IV) infusion in the clinic (an IV infusion means the drug will be delivered through a tube in your vein). Patient will then self-administer ACT001 capsules twice daily by mouth, at the dose to which patient is assigned, until the evening prior to scheduled surgery. Patient then will undergo surgery to remove all or part of tumor.
Study NCT05090943 — intervention group
Intervention type: OTHER
Intervention: QOL to be completed by the participant
Description: The scales (PUTS, OCI, TS-QOL, ASRS, GAD-7, PHQ9, TAPS) to be completed by the participant
Study NCT04812314 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will complete a moderate intensity continuous exercise 4 days/week.
Study NCT04812314 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No exercise
Description: Participants will remain sedentary throughout the duration of the study.
Study NCT05485480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional opioid-based group
Description: In addition to propofol as a hypnotic and rocuronium as a muscle relaxant, patients in the conventional opioid-based group will receive the following drugs: Remifentanil and Fentanyl
Study NCT05485480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: opioid-sparing group
Description: In addition to propofol as a hypnotic and rocuronium as a muscle relaxant, patients in the opioid-sparing group will receive Ketamine, Fentanyl, Lidocaine, Magnesium, Clonidine, Remifentanil
Study NCT05451667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YJ001 for Spray Use
Description: YJ001 (active ingredient)
Study NCT05451667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of YJ001 for Spray Use
Description: Hydroxypropyl Methylcellulose
Study NCT05986045 — intervention group
Intervention type: OTHER
Intervention: Quality of Life
Description: ENHANCE will collect natural history on all children with cystic fibrosis who are enrolled over a 5 year period
Study NCT06136104 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mixhers HERTIME
Description: A daily self-administered powder supplement packet mixed into water.
Study NCT06136104 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A daily self-administered powder placebo supplement packet mixed into water.
Study NCT05590442 — intervention group
Intervention type: OTHER
Intervention: Tests
Description: Cognitive assessments and olfactory tests
Study NCT05335200 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: (S)-[18F]FBFP PET/CT
Description: Patients will be intravenously injected with 185-370MBq (S)-\[18F\]FBFP and undergo serial whole-body PET/CT scans at multiple time points (5min, 15min, 30min, 45min, 1h, 2h, 4h). Safety assessment and tolerability of the study will be conducted.
Study NCT05145543 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9%
Description: 0.9 NaCl % (Saline) (5 ml) will be applied
Study NCT05145543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine Hydrochloride
Description: 0.25 % levobupivacaine (5 ml) will be applied.
Study NCT05145543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine Hydrochloride
Description: 0.25 % levobupivacaine (5 ml) will be applied.
Study NCT05145543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: fentanyl plus 0.25 % levobupivacaine (5 ml) will be applied.
Study NCT05145543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone plus levobupivacaine (5 ml) will be applied.
Study NCT05398796 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA -1215
Description: mRNA-1215 is a novel mRNA vaccine that encodes for the secreted prefusion stabilized F component covalently linked to G monomer (pre-F/G) of Malaysian strain NiV, resulting in a post-expression trimerization.
Study NCT05024656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AmnioExcel Plus Amniotic Membrane
Description: AmnioExcel® Plus will be applied weekly, in conjunction with SOC, if the ulcer remains open, or up to and including Week 11, whichever comes first.
Study NCT05024656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: The dressings, materials, and appliances used in accordance with institutional protocol or professional clinical judgement.
Study NCT05024656 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The dressings, materials, and appliances used in accordance with institutional protocol or professional clinical judgement.
Study NCT04995263 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sueña component 1: Sleep Hygiene Promotion
Description: The nursery staff will be instructed to promote sleep hygiene. Nurse technicians will: inform patients of the efforts to ensure a healthy sleep environment, verify the minimization of light and noise after 23:00 PM, favour natural light after 07:00 AM, and foment patient's activities and participation in group therapy. Nurses will: reduce sleep interruptions to a minimum, to only perform actions (i.e. blood testing, clinical controls, medicine administration) deemed strictly necessary between 23:00 PM and 07:00 AM. A list of commonly used medications with their pharmacodynamic and pharmacokinetic properties tailored by a pharmaceutical chemist will be provided, to ensure optimal medication administration while protecting the guaranteed sleep hours, to be coordinated with the treating physician.
Study NCT05435053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Every 2 weeks (3 mg/kg, maximum of 240 mg) for up to 24 weeks~Nivolumab is an immune checkpoint inhibitor (PD-1-inhibitor).
Study NCT05435053 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Description: Percutaneous ablation of a primary in-situ (or locally-recurrent) or metastatic lesion.~Irreversible electroporation is delivered through the NanoKnife system (AngioDynamics, New York, USA). The system is FDA-approved for medical use.
Study NCT04995263 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sueña component 2: Periodic Anxiety and Pain Screening
Description: Every night, nursery staff will include anxiety and pain screenings as part of vital signs assessments, using visual analog scales for each one. If any screening is altered, clinical actions will be performed to alleviate symptomatology if deemed necessary, using clinical judgement.
Study NCT04995263 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sueña component 3: Hypnotics and Caffeine Regulation
Description: The use of hypnotics will be standardized to be administered no later than at 22:00 PM; in the case of melatonin, its administration will be suggested at sundown, at 20:00 PM. Caffeinated drinks will be prohibited after 15:00 PM.
Study NCT04995263 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sueña component 4: Sleep Masks and Ear Plugs
Description: Sleep masks and ear plugs will be available to all patients if they wish to use them. The nursery team will reinforce its use between 23:00 PM and 07:00 AM.
Study NCT04995263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sueña component 5: Personalized Psychoeducation
Description: Two individualized, nurse-led psychoeducation PowerPoint presentations on sleep hygiene will be presented to patients, supported by educational material aimed at the patient and their families.
Study NCT04995263 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sueña component 6: Sleep Reports
Description: Objective and subjective reports of sleep quality will be handed to attending psychiatrist, using data gathered with wearable devices (Fitbit Charge 4) and self-report questionnaires regarding perceived sleepiness and overall sleep. The psychiatrist in charge uses said information in the routine case management
Study NCT04273997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole 10% ointment
Description: Metronidazole 10% ointment
Study NCT04273997 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ointment
Description: Placebo ointment
Study NCT06355726 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma Exchange
Description: Plasma exchange session will be done on alternate day to a maximum of 5 sessions. PLEX will be discontinued if the patients Shows sustained clinical improvement, Receive liver transplantation, Refuses further PLEX session,no improvement in clinical condition and Intolerant to PLEX procedure
Study NCT06355726 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment
Study NCT06355726 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment
Study NCT06129097 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Thyme honey mouthwash
Description: * Thyme honey will be applied as oral rinse.~* Based on this protocol, patients will have oral rinses (20 ml of thyme honey diluted in 100 ml of purified water) 3 times per day.~* Patients will be instructed to perform thyme honey rinses in the oral mucosa.~* Patients will be instructed not to swallow the thyme honey oral rinse.
Study NCT06129097 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thyme honey mouthwash
Description: * Thyme honey will be applied as oral rinse.~* Based on this protocol, patients will have oral rinses (20 ml of thyme honey diluted in 100 ml of purified water) 3 times per day.~* Patients will be instructed to perform thyme honey rinses in the oral mucosa.~* Patients will be instructed not to swallow the thyme honey oral rinse.
Study NCT05578677 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biopsy technique
Description: * Using the turn-and-suction technique, the forceps cups are opened and the forceps is withdrawn against the tip of the endoscope. The tip is then directed toward the target ('turn'), and suction is applied ('suction') as the forceps is applied against the targeted mucosa and then closed.~* Endoscopists can obtain two biopsy specimens from a single passage of the conventional biopsy forceps instead of one. These techniques are called the 'double-biopsy method' and the 'single-biopsy method', respectively.
Study NCT04676724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3228836
Description: Participants will be administered GSK3228836.
Study NCT05725772 — intervention group
Intervention type: OTHER
Intervention: Location of Visit
Description: Participants will perform visits 1) at-home via telemedicine, 2) in-person and 3) at a local regional clinic via telemedicine
Study NCT04676724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFN
Description: Participants will be administered PegIFN.
Study NCT04676724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NA therapy
Description: Participants will continue to receive their NA therapy for the duration of the study.
Study NCT04844008 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nanobubble drink
Description: Commercially available sports drink
Study NCT04844008 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nanobubble drink
Description: Commercially available sports drink
Study NCT05362149 — intervention group
Intervention type: DRUG
Intervention: Darolutamide (Nubeqa, BAY1841788)
Description: Retrospective cohort analysis, using PPS EMR prostate cancer database in the US.
Study NCT05362149 — intervention group
Intervention type: DRUG
Intervention: Enzalutamide
Description: Retrospective cohort analysis, using PPS EMR prostate cancer database in the US.
Study NCT05362149 — intervention group
Intervention type: DRUG
Intervention: Apalutamide
Description: Retrospective cohort analysis, using PPS EMR prostate cancer database in the US.
Study NCT05631704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VH4524184
Description: VH4524184 will be administered.
Study NCT05631704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Midazolam will be administered in the highest dose cohort in Part 2 (Cohorts 8 or 9).
Study NCT05631704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam will be administered in the highest dose cohort in Part 2 (Cohorts 8 or 9).
Study NCT05631704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.
Study NCT05769946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay005
Description: A PDE-4 inhibitor
Study NCT05769946 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hemay005
Description: A PDE-4 inhibitor
Study NCT06046417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramlintide
Description: Pramlintide delivered in a basal-bolus manner.
Study NCT06046417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyumjev
Description: Lyumjev delivered in a basal-bolus manner.
Study NCT06046417 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lyumjev
Description: Lyumjev delivered in a basal-bolus manner.
Study NCT06046417 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated Insulin Delivery (AID) system
Description: The AID system consists of a set of devices that work inter-connectedly to automate insulin (and pramlintide) delivery in response to an individual's glucose levels. It consists of a (i) Dexcom G6 glucose sensor, (ii) a smartphone-based algorithm, (iii) an insulin YpsoPump, and (iv) a pramlintide/placebo YpsoPump in a dual hormone configuration.
Study NCT04794153 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whole food sources
Description: Foods selected are naturally high in protein and consumed by the general population as part of a meal.
Study NCT04794153 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: whole food sources
Description: Foods selected are naturally high in protein and consumed by the general population as part of a meal.
Study NCT05762640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Form: tablets, 50 mg/m2/day in two administrations. Maximum dose is 100 mg/day. Administration in association with Methylprednisolone IV (or Prednisolone PO) starting at 2 mg/kg/day in two administrations.~Duration of treatment: until D-1 of conditioning for allogeneic HSCT OR 9weeks for patients who are not eligible for HSCT.
Study NCT06285071 — intervention group
Intervention type: DRUG
Intervention: Concizumab
Description: Participants will be treated with commercially available Alhemo (Concizumab) according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Concizumab has been made by the participant/ legally acceptable representative (LAR) and the treating physician before and independently from the decision to include the participant in this study.
Study NCT00063804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Study NCT00063804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD070
Study NCT06481943 — intervention group
Intervention type: DEVICE
Intervention: Sponsor MCG device (CardiAQ)
Description: Unshielded magnetocardiography device for measuring cardiac magnetic fields
Study NCT05516771 — intervention group
Intervention type: DEVICE
Intervention: Tcore™ system
Description: The Tcore sensor is a double-sensor-heat-flux (DHF) thermometer and consist of two sensors separated by a known thermal resistance. One side is placed directly at the patient's skin and the other is facing the environment. After some equilibration time the core temperature can then be calculated. The sensors are placed above the eye and the sinus frontalis.~Intended use The Tcore system is a thermometer intended for non-invasive, continuous measurement of the core body temperature of children from 5 years of age, adolescents, and adults. The Tcore system consists of a sensor and an adapter. The adapter is reusable. The sensor is intended for single use. The Tcore system works in adjusted mode, i.e., the core body temperature is determined by a dual sensor.~Off-Label/Investigational Use In context of this clinical study the Tcore-system will be investigated outside its approved and intended use, namely in children below the age of five and toddlers.
Study NCT05460858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: One hundred and forty participants randomize in the intervention and placebo groups, during 6 weeks simultaneous to start standard long agonist protocol or antagonist induction. They will be received 1200 (2×600) mg of effervescent tablets of NAC or placebo daily. Plasma blood will collect before the intervention and at the time of oocyte retrieval (end of 6 week), in addition to, follicular fluid will be obtained from the mature follicles.
Study NCT05460858 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT06252155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Mothers will listen to music for 30 minutes every day for 2 postpartum days. The type of music to be used in this study will be Turkish music . Turkish music will be preferred in the study because it is a part of the culture in which the study will be conducted. This type of music was preferred because it evokes feelings of happiness, laughter, joy, power, courage and heroism in the human soul. In deciding the type of music listened to in the study, expert opinion was taken from a faculty member teaching music therapy at a state university. During the music session, the mother will take a comfortable position on the sofa or bed. She will also be asked to close her eyes and imagine where she wants to be. She will also be asked to breathe slowly and deeply to regulate her breathing. The mother will be told to feel comfortable, to feel her body relax from head to toe while listening to music, to focus on the music and to free her thoughts.
Study NCT05940961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: intravenous infusion: Cycle 1: D1 0.8mg/m2, D8 0.5mg/m2, D15 0.5mg/m2, if the MRD turn negative, cycle 2: D1 0.5mg/m2, D8 0.5mg/m2, D15 0.5mg/m2， if not，cycle 2: D1 0.8mg/m2, D8 0.5mg/m2, D15 0.5mg/m2
Study NCT04075136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Intravitreal injection 0.5 MG Per 0.05 ML Injection.
Study NCT04075136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Intravitreal injection 0.5 MG Per 0.05 ML Injection.
Study NCT04075136 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photodynamic laser treatment (PDT)
Description: PDT light dose of 50 J/cm2 of neovascular lesion administered at an intensity of 600mW/cm2. A Visudyne infusion will be administered for the PDT portion of the treatment at a dose of 6mg/m2 body surface area. PDT will be administered at half-fluence - measured by time, i.e. 42 seconds as opposed to full-fluence which is 83 seconds.
Study NCT04075136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: Intravitreal injection of 0.5ml-2mg
Study NCT04075136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: verteporfin
Description: Visudyne infusion will be administered for the PDT portion of the treatment at a dose of 6mg/m2 body surface area.
Study NCT06477640 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The intervention group will receive daily activity messages sent through SMS text message or email.The messages will provide daily exercises with heart rate guidance.
Study NCT06477640 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: The control group will receive daily non-descript messages to help with blinding and to eliminate the confounding variable of daily contact. The messages will not include activity tasks and will include phrases such as I hope you have a good day.
Study NCT05473793 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dried chicory root particles
Description: The intervention product consists of chicory root that have been sliced and dried and are provided in the form of particles (\~3mm).
Study NCT05473793 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control arm receives a placebo consisting of rice puff particles.
Study NCT05013632 — intervention group
Intervention type: DRUG
Intervention: Antiviral Agents
Description: Antiviral medications indicated for the treatment of mild to severe COVID-19
Study NCT05013632 — intervention group
Intervention type: DRUG
Intervention: Monoclonal antibody
Description: Monoclonal antibodies indicated for the treatment of mild to severe COVID-19